Over the years, our researchers’ discoveries have been developed into various commercial ventures with the aim of translating their findings into clinics and benefiting patients.
In this video, we spoke with some current and former Group Leaders from across the MRC WIMM about their companies and how the environment at the Institute helped to make them happen.
Ahmed Ahmed co-founded Singula Bio, together with Enda McVeigh and the late Enzo Cerundolo, to pioneer immunological, medical, surgical and computational technologies to generate selective therapies that eliminate cancer.
Beth Psaila co-founded Alethiomics with fellow MRC WIMM Group Leader Adam Mead. Alethiomics aims to apply innovations in single cell multi-omic analysis to develop novel therapeutics for blood cancers.
Bent Jakobsen is a former Group Leader at the MRC WIMM, who founded Avidex in 1999 based on his group’s research into the recognition of human leukocyte antigen (HLA) peptide antigens by T-cell receptors. Avidex was sold to MediGene in 2006 and the TCR technology was further developed by Immunocore and Adaptimmune, which Bent co-founded with James Noble.
Read the story on the MRC Weatherall Institute of Molecular Medicine website.